About this Research Topic
Although there have been significant advances in the rational design of metal compounds for cancer treatment, the high occurrence of resistance and severe side effects associated with chemotherapy are still a challenge. New generations of metal compounds with new mechanisms of action, broader spectra, and improved anticancer properties are still needed. In this context, several inorganic and organometallic complexes of ruthenium, iron, gold, copper, osmium, cobalt, and titanium, among other metals, appear to be promising alternatives for cancer therapy. The combination of different therapeutic strategies aiming to target several different pathways within cancer cells, as well as the use of drug delivery platforms fostered by nanotechnology, might improve efficacy, however there are several hurdles for their effective translation.
The aim of this Research Topic is to cover the most recent developments in the field of metal compounds for cancer therapy. This Research Topic welcomes the submission of Original Research articles, Perspectives, and Reviews focused on, but not limited to, the following topics:
• Design and synthetic strategies of new inorganic/organometallic compounds bearing antitumor activity
• Biological evaluation of novel metal compounds
• Mechanism of action (molecular targets/pathways involved)
• Pharmacological properties of compounds
• Drug delivery and novel therapeutic strategies
Topic Editors Alexandra Fernandes and Pedro Baptista are co-founders of Nano4 Global, a start-up dedicated to molecular nanodiagnostics. Dr. Fernandes is also co-founder of Heartgenetics SA, and Dr. Baptista holds a patent on optical sensors. The other Topic Editors declare no conflicting interests.
Keywords: cancer chemotherapy, inorganic/organometallic, medicinal chemistry, metal-based drug design, drug delivery, mechanism of action, nanomedicine
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.